Forsta AP Fonden Lowers Stock Holdings in Healthpeak Properties, Inc. $DOC

Forsta AP Fonden lowered its holdings in Healthpeak Properties, Inc. (NYSE:DOC) by 33.9% in the fourth quarter, Holdings Channel.com reports. The firm owned 275,200 shares of the real estate investment trust’s stock after selling 141,300 shares during the period. Forsta AP Fonden’s holdings in Healthpeak Properties were worth $4,425,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. State Street Corp grew its position in shares of Healthpeak Properties by 1.8% in the third quarter. State Street Corp now owns 49,498,109 shares of the real estate investment trust’s stock valued at $947,889,000 after purchasing an additional 895,460 shares during the period. JPMorgan Chase & Co. grew its position in shares of Healthpeak Properties by 41.0% in the third quarter. JPMorgan Chase & Co. now owns 28,236,534 shares of the real estate investment trust’s stock valued at $540,730,000 after purchasing an additional 8,212,504 shares during the period. Geode Capital Management LLC grew its position in shares of Healthpeak Properties by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 19,534,041 shares of the real estate investment trust’s stock valued at $312,959,000 after purchasing an additional 123,274 shares during the period. Cullen Capital Management LLC grew its position in shares of Healthpeak Properties by 6.7% in the third quarter. Cullen Capital Management LLC now owns 10,232,875 shares of the real estate investment trust’s stock valued at $195,960,000 after purchasing an additional 641,771 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in shares of Healthpeak Properties by 4.1% in the third quarter. Dimensional Fund Advisors LP now owns 10,228,560 shares of the real estate investment trust’s stock valued at $195,873,000 after purchasing an additional 400,900 shares during the period. Hedge funds and other institutional investors own 93.57% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on DOC. Argus downgraded Healthpeak Properties from a “buy” rating to a “hold” rating in a research report on Thursday, February 5th. Wall Street Zen raised Healthpeak Properties from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. Citigroup boosted their price target on Healthpeak Properties from $17.50 to $20.00 and gave the company a “neutral” rating in a research report on Tuesday, May 12th. Evercore downgraded Healthpeak Properties from an “outperform” rating to an “in-line” rating and set a $21.00 price target for the company. in a research report on Monday, May 11th. Finally, Weiss Ratings raised Healthpeak Properties from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 8th. Four investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $19.38.

Insider Activity at Healthpeak Properties

In other Healthpeak Properties news, insider Scott R. Bohn sold 10,989 shares of the business’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $19.45, for a total transaction of $213,736.05. Following the transaction, the insider owned 7,636 shares in the company, valued at $148,520.20. The trade was a 59.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.23% of the stock is currently owned by corporate insiders.

Healthpeak Properties Price Performance

DOC stock opened at $19.46 on Wednesday. The stock has a 50-day moving average price of $17.76 and a two-hundred day moving average price of $17.33. Healthpeak Properties, Inc. has a 12-month low of $15.70 and a 12-month high of $20.27. The company has a current ratio of 2.96, a quick ratio of 2.96 and a debt-to-equity ratio of 1.15. The company has a market cap of $13.41 billion, a PE ratio of 60.80, a price-to-earnings-growth ratio of 2.97 and a beta of 1.05.

Healthpeak Properties (NYSE:DOC) last posted its quarterly earnings results on Tuesday, May 5th. The real estate investment trust reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.02. Healthpeak Properties had a return on equity of 2.61% and a net margin of 7.73%.The firm had revenue of $752.95 million during the quarter, compared to the consensus estimate of $694.59 million. During the same quarter in the previous year, the business earned $0.46 earnings per share. The firm’s quarterly revenue was up 7.1% compared to the same quarter last year. Healthpeak Properties has set its FY 2026 guidance at 1.710-1.750 EPS. As a group, research analysts predict that Healthpeak Properties, Inc. will post 1.74 EPS for the current year.

Healthpeak Properties Dividend Announcement

The business also recently disclosed a monthly dividend, which will be paid on Friday, June 26th. Shareholders of record on Monday, June 15th will be paid a dividend of $0.1017 per share. This represents a c) dividend on an annualized basis and a dividend yield of 6.3%. The ex-dividend date is Monday, June 15th. Healthpeak Properties’s payout ratio is currently 381.25%.

Healthpeak Properties Company Profile

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.